Thc Therapeutics Inc Financials
This page shows Thc Therapeutics Inc (THCT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Thc Therapeutics Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Thc Therapeutics Inc generates $0.22 in operating cash flow (-$85K OCF vs -$387K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Thc Therapeutics Inc earns $-6.2 in operating income for every $1 of interest expense (-$494K vs $80K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Thc Therapeutics Inc generated $0 in revenue in fiscal year 2023.
Thc Therapeutics Inc's EBITDA was -$493K in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 71.6% from the prior year.
Thc Therapeutics Inc reported -$387K in net income in fiscal year 2023. This represents an increase of 74.5% from the prior year.
Thc Therapeutics Inc held $10 in cash against $0 in long-term debt as of fiscal year 2023.
Thc Therapeutics Inc had 33M shares outstanding in fiscal year 2023. This represents a decrease of 4.1% from the prior year.
Thc Therapeutics Inc spent $0 on share buybacks in fiscal year 2023, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 100.0% from the prior year.
THCT Income Statement
| Metric | Q3'24 | Q2'24 | Q1'24 | Q3'23 | Q3'23 | Q2'23 | Q1'23 | Q2'22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | N/A | $0 | $0 | $0 | N/A |
| Cost of Revenue | $0 | $0 | $0 | N/A | $0 | $0 | $0 | N/A |
| Gross Profit | $0 | $0 | $0 | N/A | $0 | $0 | $0 | N/A |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $9K+24.2% | $7K+465.9% | $1K | N/A | $3K-94.1% | $58K+644.6% | $8K | N/A |
| Operating Income | -$380K-345.9% | -$85K-54.2% | -$55K | N/A | -$58K+78.8% | -$274K-154.4% | -$108K | N/A |
| Interest Expense | $18K-6.8% | $20K+1.5% | $19K | N/A | $19K-4.2% | $20K-0.3% | $20K | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | $105K+118.3% | -$572K-815.4% | -$62K | N/A | $94K-94.4% | $1.7M+179.0% | -$2.1M | N/A |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
THCT Balance Sheet
| Metric | Q3'24 | Q2'24 | Q1'24 | Q3'23 | Q3'23 | Q2'23 | Q1'23 | Q2'22 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $12K-20.3% | $15K+27.0% | $12K-10.2% | $13K-2.7% | $13K-42.0% | $23K-59.3% | $57K-72.6% | $207K |
| Current Assets | $849-75.8% | $4K+35010.0% | $10-99.0% | $980-0.5% | $985-90.5% | $10K-76.3% | $44K+7.0% | $41K |
| Cash & Equivalents | $849-75.8% | $4K+35010.0% | $100.0% | $10-33.3% | $15-99.8% | $9K+148.1% | $4K+11028.1% | $32 |
| Inventory | N/A | N/A | $0 | $0 | $0 | $0 | N/A | $25 |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $3.5M-9.7% | $3.9M+15.5% | $3.4M+1.8% | $3.3M+1.0% | $3.3M-3.1% | $3.4M-35.7% | $5.3M+59.2% | $3.3M |
| Current Liabilities | $3.4M-9.9% | $3.8M+16.0% | $3.3M+1.9% | $3.2M+1.0% | $3.2M-3.2% | $3.3M-36.4% | $5.2M+61.0% | $3.2M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$3.5M+9.6% | -$3.9M-15.5% | -$3.4M-1.9% | -$3.3M-1.0% | -$3.3M+2.8% | -$3.4M+35.5% | -$5.2M-67.9% | -$3.1M |
| Retained Earnings | -$39.0M+0.3% | -$39.1M-1.5% | -$38.5M-0.2% | -$38.4M-0.1% | -$38.4M+0.2% | -$38.5M+4.2% | -$40.2M-5.6% | -$38.0M |
THCT Cash Flow Statement
| Metric | Q3'24 | Q2'24 | Q1'24 | Q3'23 | Q3'23 | Q2'23 | Q1'23 | Q2'22 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$137K-203.7% | -$45K-16676.2% | -$269-472.3% | -$47+97.8% | -$2K+96.5% | -$62K-187.3% | -$21K+8.8% | -$24K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Financing Cash Flow | $134K+176.4% | $49K+17977.7% | $269+540.5% | $42+100.6% | -$7K-109.9% | $67K+167.8% | $25K+26.5% | $20K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | $0 | $0 | N/A | N/A | $0 |
THCT Financial Ratios
| Metric | Q3'24 | Q2'24 | Q1'24 | Q3'23 | Q3'23 | Q2'23 | Q1'23 | Q2'22 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | 885.7%+4745.4pp | -3859.7%-3324.3pp | -535.5% | N/A | 707.0%-6613.2pp | 7320.2%+11090.2pp | -3770.0% | N/A |
| Current Ratio | 0.000.0 | 0.000.0 | 0.000.0 | 0.000.0 | 0.000.0 | 0.000.0 | 0.010.0 | 0.01 |
| Debt-to-Equity | -1.000.0 | -1.000.0 | -1.000.0 | -1.000.0 | -1.000.0 | -1.010.0 | -1.01+0.1 | -1.07 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$3.4M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Thc Therapeutics Inc's annual revenue?
Thc Therapeutics Inc (THCT) reported $0 in total revenue for fiscal year 2023. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Thc Therapeutics Inc profitable?
No, Thc Therapeutics Inc (THCT) reported a net income of -$387K in fiscal year 2023.
What is Thc Therapeutics Inc's EBITDA?
Thc Therapeutics Inc (THCT) had EBITDA of -$493K in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization.
What is Thc Therapeutics Inc's operating cash flow?
Thc Therapeutics Inc (THCT) generated -$85K in operating cash flow during fiscal year 2023, representing cash generated from core business activities.
What are Thc Therapeutics Inc's total assets?
Thc Therapeutics Inc (THCT) had $12K in total assets as of fiscal year 2023, including both current and long-term assets.
How many shares does Thc Therapeutics Inc have outstanding?
Thc Therapeutics Inc (THCT) had 33M shares outstanding as of fiscal year 2023.
What is Thc Therapeutics Inc's current ratio?
Thc Therapeutics Inc (THCT) had a current ratio of 0.00 as of fiscal year 2023, which is below 1.0, which may suggest potential liquidity concerns.
What is Thc Therapeutics Inc's debt-to-equity ratio?
Thc Therapeutics Inc (THCT) had a debt-to-equity ratio of -1.00 as of fiscal year 2023, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Thc Therapeutics Inc's return on assets (ROA)?
Thc Therapeutics Inc (THCT) had a return on assets of -3316.8% for fiscal year 2023, measuring how efficiently the company uses its assets to generate profit.
What is Thc Therapeutics Inc's cash runway?
Based on fiscal year 2023 data, Thc Therapeutics Inc (THCT) had $10 in cash against an annual operating cash burn of $85K. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Thc Therapeutics Inc's debt-to-equity ratio negative or unusual?
Thc Therapeutics Inc (THCT) has negative shareholder equity of -$3.4M as of fiscal year 2023, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Thc Therapeutics Inc's Piotroski F-Score?
Thc Therapeutics Inc (THCT) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Thc Therapeutics Inc's earnings high quality?
Thc Therapeutics Inc (THCT) has an earnings quality ratio of 0.22x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Thc Therapeutics Inc cover its interest payments?
Thc Therapeutics Inc (THCT) has an interest coverage ratio of -6.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.